β-NETA is primarily used in the field of nuclear medicine as a chelating agent for radiolabeling peptides and antibodies. It plays a crucial role in the development of radiopharmaceuticals, which are used for diagnostic imaging and targeted cancer therapy. The compound forms stable complexes with radioactive metals like technetium-99m, enabling the delivery of these isotopes to specific tissues or tumors. This targeted approach enhances the accuracy of imaging techniques such as SPECT (Single Photon Emission Computed Tomography) and improves the efficacy of therapeutic treatments by minimizing damage to healthy cells. Additionally, β-NETA is utilized in research to study receptor-binding properties and optimize radiopharmaceutical design for better diagnostic and therapeutic outcomes.